The therapeutical efficacy of senolytic drugs in the treatment of non-alcoholic fatty liver disease with fibrosis - the truth study
- Conditions
- Hepatic SteatosisAFLD met leverfibroseNon-Alcoholic Fatty Liver Disease
- Registration Number
- NL-OMON53809
- Lead Sponsor
- vasculaire geneeskunde
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 33
- Diagnosis of NAFLD with fibroses score *2 on liver biopsy
- Diagnosis of DM type 2 on stable metformin
- No hepatis B and/or C
- 18-70 years of age
- Subjects should be able to give informed consent
- Compromised immunity - Use of anticoagulants - QTc>450 msec on ECG - Known
genetic basis for insulin resistance or glucose intolerance - Ethanol intake >
14 U/week - Pregnancy, females who are breastfeeding - Auto-immune hepatitis -
Wilson disease3/ alpha 1-antitripsine deficiency - Hemochromatosis - When
subjects use drugs that are dependent on CYP3A4 with narrow therapeutic window
and strong inducers or inhibitors of CYP3A4 , the responsible clinician will be
consulted to discuss the necessity of dose modification or alternative drug
replacement. When this is not optional, subjects will be excluded. - Use of
H2-antagonists and/or proton pump inhibitors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method